Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

NO_LONGER_AVAILABLE

Conditions studied: Solid Tumors

In brief

Open-label, continuation study

Key facts

Study ID

NCT02354612

Run by

Tracon Pharmaceuticals Inc.

Last updated by the study team

2021-02-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participation in a TRACON Pharmaceuticals sponsored parent TRC105 study and, thought to have potential to derive clinical benefit from continued treatment with TRC105 in the opinion of the parent study investigator.
• Willing and able to consent for self to participate in study
• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• 18 years of age or older
• ability to begin TRC105 dosing on this protocol within 6 weeks from the subjects last dose of TRC105 in the parent TRC105 study

You may not qualify if…

• Any clinical event that would make TRC105 therapy inappropriate under the parent protocol
• Current treatment in another clinical study
• Pregnant or breastfeeding
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator, would make the subject inappropriate for entry into the study

Where it is running

• UCLA — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.